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Enteroendocrine cells, which secrete peptide hormones in response to sensation of food and gut microbiota
products, can now be genetically tagged, isolated, cultured, and characterized for expression of the elusive
chemosensors, as shown in publications inPNAS (Samuel et al., 2008) and in this issue (Reimann et al., 2008).The enteroendocrine system constitutes
the largest but also the least well under-
stood endocrine organ of the body.
Throughout the GI tract, enteroendocrine
cells are found scattered in the epithelium
among the enterocytes (Rindi et al., 2004).
Typically these cells are conically shaped
with a small apical pole decorated with
microvilli facing the gut lumen and a
broader base where peptide hormones
are released from dense-core secretory
granules (Figure 1). These cells often
have basal, dendrite-like cytoplasmic
processes for directed paracrine and
apparently also for sensory functions
(Larsson et al., 1979; Karaki et al., 2006).
More than a dozen different types of en-
teroendocrine cells have been described
based on morphological and immuno-
histochemical differences (Rindi et al.,
2004)—and the corresponding list of gut
hormones is even longer and probably
far from complete yet (Figure 1). A major
problem in this field of research has been
that the enteroendocrine cells are difficult
to study directly. This situation will change
significantly as a result of two papers—
one by Reimann and coworkers in this
issue (Reimann et al., 2008) and another
recently published by Samuel and co-
workers (Samuel et al., 2008). In both
studies specific enteroendocrine cell
types are tagged genetically through the
expression of a fluorescent protein under
the control of the promoter for a peptide
hormone precursor, i.e., proglucagon
(GLP-1) and pro-CCK, respectively. This
allows for subsequent isolation, purifica-
tion by FACS, and even culturing of the
specific subpopulation of cells. Conse-
quently, individual enteroendocrine celltypes can now—finally—be studied di-
rectly by biochemical and molecular biol-
ogy techniques. For example, the primary
cultures of purified GLP-1-producing
L cells are subjected to detailed electro-
physiology, fluorescence calcium imag-
ing, and gene expression analysis—all
illuminating novel aspects of enteroendo-
crine cell biology (Reimann et al., 2008).
Multiple, especially metabolic functions
are regulated by gut hormones, which
send information about the conditions in
the various segments of the GI tract to a
wide spectrum of organs and tissues in
the body. These hormones function both
through classical endocrine mechanisms
and frequently also through activation of
afferent, sensory nerves—i.e., in addition
to their local, paracrine functions (Fig-
ure 1). Especially the effects of gut hor-
mones on pancreatic endocrine function,
on appetite, and on gastrointestinal motil-
ity have positioned several of these pep-
tides in the front of the race for novel treat-
ments for type 2 diabetes and obesity,
i.e., GLP-1 mimetics (exenatide and lira-
glutide) and indirectly DDP-IV inhibitors.
However, PYY and PP mimetics are also
in clinical trials for obesity and diabetes,
GLP-2 mimetics are being tested in che-
motherapy-induced diarrhea and osteo-
porosis, and ghrelin mimetics for cancer
cachexia and gut motility disorders.
For decades it has been known that the
presence and nature of distinct food com-
ponents in the lumen of the GI tract—pro-
teins, lipids, and carbohydrates—are the
main regulator of the secretion of individ-
ual gut hormones (Figure 1). However, it is
only during the last couple of years that
we have begun to understand the molec-Cell Metabolism 8,ular basis for this important differentiated
sensing of gut contents. A number of or-
phan receptors were recently shown to
be activated, for example, by long-chain
fatty acids (LCFA), by short-chain fatty
acids (SCFA), by proteolytic degradation
products, and by bile acids (Brown et al.,
2005; Choi et al., 2007; Katsuma et al.,
2005) (Figure 1). Several of these recep-
tors have recently, in different ways,
been specifically linked to enteroendo-
crine cells, and it was assumed that these
would function as the elusive chemosen-
sors of the enteroendocrine system in
general (Karaki et al., 2006; Choi et al.,
2007; Covington et al., 2006). Reimann
and coworkers can now by QPCR analy-
sis show that pure L cells express not only
the acylethanolamine receptor GPR119
but also the LCFA receptors GPR40 and
GPR120 and the bile acid receptor
GPR131 (TGR5)—none of which are ex-
pressed in the non-enteroendocrine cell
fraction.
Samuel and coworkers specifically
focus on the SCFA receptor GPR41 and
mainly use the isolated enteroendocrine
cells to demonstrate that these cells, in
contrast to the surrounding cells, express
GPR41 (Samuel et al., 2008). SCFAs such
as proprionate, acetate, and butyrate are
generated in the gut lumen through micro-
bial degradation of complex polysaccha-
rides. Both rodent and human studies
have suggested that gut microbiota and
the generated SCFAs could contribute
significantly to host energy balance and
to adiposity (Turnbaugh et al., 2006,
2008). By use of GPR41-deficient mice,
Samuel and coworkers now show that
the SCFAs apparently function not onlyDecember 3, 2008 ª2008 Elsevier Inc. 447
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PreviewsFigure 1. A Schematic Overview of Sensory and Secretory Functions of Enteroendocrine Cells of the Gut
Between two enterocytes, a prototypical, conical enteroendocrine cell is shown in green with its microvillus decorated apical pole reaching the gut lumen and with
peptide hormone-filled secretory granules at the base. In the blue box to the right are listed a selection of classical gut hormones and with red arrows at the bottom
are indicated the three main modes of action of such hormones: paracrine (and autocrine), neuronal, and endocrine functions. At the top are indicated the three
main food components that are known to regulate gut hormone expression and secretion (proteins, lipids, and carbohydrates) and some of the main metabolites
that are believed to be sensed by the enteroendocrine cells (LCFA, long-chain fatty acids; SCFA, short-chain fatty acids). The gut microbiota is responsible for
degrading complex polysaccharides to the main SCFAs: propionate, acetate, and butyrate. Secretory products such as bile acids—but conceivably also other
components—from more proximal parts of the GI tract also affect enteroendocrine function. In the red box to the left are listed a number of 7TM G protein-coupled
receptors that today are assumed to function as chemosensors in the enteroendocrine cells (GPR131 is still often called TGR5). By small, red serpentine symbols
are indicated the presumed location of these chemosensors on the basolateral membrane of the cell (Karaki et al., 2006), and potentially also at the apical pole.
Long black arrows—for simplicity only shown for SCFA and bile acids—indicate that a major site for chemosensing very likely could be the lateral space between
the enteroendocrine cell and the enterocytes. Small, black serpentine symbols indicate 7TM receptors for hormones and neurotransmitters (neuropeptides and
monoamines) and for the gut hormones themselves.as fuel but that they may act also as
signaling molecules because the GPR41
receptor is required for the full metabolic
effect of these metabolites (Samuel et al.,
2008). The increase in body and fat pad
weight, which is normally observed in
germ-free mice upon colonization with
specific saccharolytic bacterial strains—
conceivably due to production of SCFA
in the colon—is not observed in GPR41/
mice. Similarly, the increase in levels of the
gut hormone PYY normally observed upon
bacterial colonization is also blunted by
deletion of GPR41. This is, by Samuel and
coworkers, being linked to the decreased
intestinal transit time observed in the
GPR41/ mice—which should lead to
decreased utilization of energy from the
diet (Samuel et al., 2008).448 Cell Metabolism 8, December 3, 2008 ªAlthough, the study by Samuel and co-
workers clearly demonstrates that GPR41
is involved in the changes in host energy
balance related to gut microbiota and its
effect on adiposity, there are still many
open ends. Notably GPR41 is not only ex-
pressed on enteroendocrine cells but is in
fact most highly expressed in adipose tis-
sue and the pancreas (Brown et al., 2005).
So, global deletion of this receptor may
also directly affect the function of these
tissues. Moreover, all PYY cells of the dis-
tal gut also express the other receptor for
SCFA, GPR43, as convincingly demon-
strated by immunohistochemistry (Karaki
et al., 2006). Consequently, it will be inter-
esting to identify the relative role of GPR41
versus GPR43 as sensors for SCFA in
the enteroendocrine system (Figure 1).2008 Elsevier Inc.Also, at least GLP-1 should be considered
as a player in the game as it is often
co-stored and -released with PYY in the
distal gut.
Nevertheless, the whole field of 7TM
chemosensors as regulators of gut hor-
mone expression and secretion is cur-
rently opening up for real. It is likely that
there are in fact several more receptors
involved in the sensing of gut contents
than those listed in the figure. Importantly,
these receptors are highly interesting drug
targets. It is currently believed that truly
efficacious regimens for obesity and
type 2 diabetes will involve various forms
of combination treatments. In principle it
should be possible instead to exploit a
‘‘natural combination treatment’’ through
modulation of 7TM chemosensors on the
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Previewsenteroendocrine cells as these cells co-
store and co-release physiological mix-
tures of gut hormones, for example
GLP-1 together with PYY and GLP-2 in
the lower gut and ghrelin together with
motilin in the upper gut. Moreover, phar-
macokinetically you may only have to ob-
tain efficient receptor exposure in the gut
epithelium—with all the benefits this
would have in respect to limited side
effects, etc. On the other hand, you may
have to ensure that the drug is released
and is active only in a particular segment
of the gut as the same chemosensor may
be used on different enteroendocrine cells
and may serve different purposes in dif-
ferent parts of the GI tract. All of this will
become much clearer when we get a bet-
ter picture of this interesting control sys-
tem through technologies as described by
Reimann and coworkers (Reimann et al.,
2008) and Samuel and coworkers (Sam-
uel et al., 2008). Nevertheless, the first
compounds that function, at least partly,
through the release of gut hormones areA Two-Step Pathw
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All vertebrate animals have develop
dictable episodes of fasting. A rec
gene activation via CRTC2 (also kno
Maintenance of glucose homeostasis is
critical to survival and well-being, as evi-
denced by the severe clinical conse-
quences resulting from diabetes. The liver
contributes to the control of glucose me-
tabolism by uptake and storage of glu-
cose after a carbohydrate-rich meal or
by the activation of glucose production
under conditions of hypoglycemia. These
processes are orchestrated by insulin,
glucagon, and glucocorticoids. Changes
in these hormone levels have a pro-
nounced effect on the hepatic transcrip-
tional program. For example, the activa-already in clinical trials, i.e., GPR119
agonists. Although the focus for these
compounds initially was on their effects
on pancreatic insulin secretion, attention
has recently included their effects on
GLP-1 release from the gut (Chu et al.,
2008). It is, however, highly likely that
GPR119 agonists will also release at least
PYY and GLP-2, because these pep-
tides—as mentioned above—are co-
stored and co-released, but possibly
also other gut hormones.
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